Close

Apricus, Abbott strike deal to commercialize Vitaros in Canada

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

Apricus Biosciences has signed a licensing deal with Abbott Laboratories, as per which Abbott will receive the exclusive rights to market Apricus Bio’s Vitaros  in Canada.

Vitaros (alprostadil), indicated to treat erectile dysfunction (ED) is applied directly as a cream that boosts blood flow.According to the collaboration deal, Abbott will commercialize and market Vitaros in Canada where the drug was approved by Health Canada in the later part of 2010.In addition, Apricus Bio will receive up to nearly $16m in up-front, regulatory and sales milestone payments, plus tiered royalty payments based on Abbott’s sales of the product in Canada.

According to the company, clinical data demonstrated that Vitaros worked in patients suffering from mild to severe ED, including men who did not respond to sildenafil citrate, while the side effects were localized and transient.

Latest stories